Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1/Smad Signaling Pathway.

Activation of HSC is a pivotal step in hepatic fibrosis. In the activation of HSC, the TGF-<italic>β</italic>1 plays a key role that can promote the occurrence of hepatic fibrosis by combining with Smad proteins. Astragaloside is the main active component extracted from<italic> Radix Astragali</italic> that has the effect of antioxidation and hepatoprotection. In the present study, we investigated the mechanism of astragalosides inhibiting hepatic fibrosis<italic> in vitro</italic> and<italic> in vivo</italic>.<italic> In vitro</italic>, astragalosides inhibited the activation of HSC and regulated the expression of MMP-2 and TIMP-2 and reduced the formation of collagen fibers.<italic> In vivo</italic>, administration of astragalosides decreased the serum ALT, AST, and TBiL in rats by reducing oxidative stress. Astragalosides also attenuated hepatic fibrosis by reducing the concentration of hydroxyproline and inhibiting the formation of collagen fibers. The expressions of TGF-<italic>β</italic>1, T<italic>β</italic>R-I, p-Smad 2, and p-Smad 3 were downregulated after astragalosides treatments, while Smad 7 was upregulated compared to the control group. The results indicated that the effect of astragaloside on hepatic fibrosis was related to the inhibition of HSC activation and the modulation of the TGF-<italic>β</italic>1/Smad signaling pathway. [ABSTRACT FROM AUTHOR]